期刊
PATHOGENS
卷 11, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/pathogens11080882
关键词
monoclonal antibodies; COVID-19; prophylaxis
类别
资金
- Italian Ministry of Health
- Esselunga S.p.A.
- Camera di Commercio, Industria e Artigianato di Roma
- Societa Numero Blu Servizi S.p.A.
- Fineco Bank S.p.A.
- Associazione magistrati della Corte dei conti
- Societa Mocerino Frutta Secca s.r.l. [395, 254, 257]
Monoclonal antibodies are protein-based substances that mimic the immune system's ability to fight off viruses. They have been authorized for the treatment and prevention of COVID-19 in high-risk individuals. This review focuses on the therapeutic indications of monoclonal antibodies for pre- and postexposure prophylaxis and the effectiveness of convalescent plasma.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful microorganisms, including viruses such as Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2). The US Food and Drug Administration (FDA) and the European Medical Agency (EMA) have already authorized monoclonal antibodies of anti-SARS-CoV-2 to treat mild to moderate CoronaVIrus Disease-2019 (COVID-19) in patients at risk of developing severe disease. More recently, monoclonal antibodies anti-SARS-CoV-2 have been authorized for primary and secondary prophylaxis in patients at high risk of severe disease for background comorbidity. Primary or pre-exposure prophylaxis prevents COVID-19 in unexposed people, whereas secondary or postexposure prophylaxis prevent COVID-19 in recently exposed people to individuals with laboratory-confirmed SARS-CoV-2. This review focuses briefly on therapeutic indications of currently available monoclonal antibodies for COVID-19 pre- and postexposure prophylaxis and on the efficacy of convalescent plasma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据